Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 3, 2014
CCS-RC (Compact Closed System – Rapid Change)
DIOSNA presents a compact, closed granulation line in "Rapid Change" design. It is a complete system for mixing, granulating and drying of pharmaceutical products in the field of R&D and clinical samples.
Advertisement
Mixing, Granulating, Drying and Coating
DIOSNA presents a compact, closed granulation line in "Rapid Change" design.
It is a complete system for mixing, granulating and drying of pharmaceutical products in the field of R&D and clinical samples.
Interchangeable product containers of different sizes from 10l to 80l are available. The system can be designed for containment applications. All current PAT systems can be integrated. A stainless steel wall in which the HMI is implemented, builds the border to the technical area. This improves the accessibility of technical components for maintenance and reduces cleanroom space.
The exhibit can be seen at the Interpack (Düsseldorf) Hall 3/E01.
Contact: Markus Nowak, Product Manager, Pharma Systems
e-mail
+49 (0)541 33104-814
Diosna Dierks & Söhne GmbH
Am Tie 23
49086 Osnabrűck
www.diosna.com
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement